Online supplementary material - Measurement of tralokinumab concentrations in serum and tear fluid of atopic dermatitis patients and the relationship with treatment response and ocular surface disease

Dekkers, C; Smeijsters, E; El Amrani, M; den Hartog Jager, C; van der Elst, K; van Luin, M; van Luijk, C; Bakker, D; Huitema, A; de Graaf, M; van Wijk, F; de Bruin-Weller, M

doi:10.5281/zenodo.15576665

Published June 2, 2025 | Version v1

Journal article Restricted

Online supplementary material - Measurement of tralokinumab concentrations in serum and tear fluid of atopic dermatitis patients and the relationship with treatment response and ocular surface disease

1. University Medical Center Utrecht

- Detailed description of the successful development and validation of the LC-MS/MS method for measuring tralokinumab concentrations in in serum and tear fluid

- Baseline characteristics

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Views

Downloads

Show more details

	All versions	This version
Views	24	24
Downloads	0	0
Data volume	0 Bytes	0 Bytes

More info on how stats are collected....

DOI

Resource type

Journal article

Publisher

Zenodo

License: Creative Commons Attribution 4.0 International

The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited. Read more

Technical metadata

Created: June 2, 2025
Modified: June 2, 2025

Online supplementary material - Measurement of tralokinumab concentrations in serum and tear fluid of atopic dermatitis patients and the relationship with treatment response and ocular surface disease

Creators

Description

Files

Restricted